PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
3820229-0	1987	Hydroxamic acid inhibitors of 5-lipoxygenase.	Hydroxamic Acids	0-15	arachidonate 5-lipoxygenase	Homo sapiens	30-44
2502629-0	1989	Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from platelets and their in vivo effects on inflammation and anaphylaxis.	Hydroxamic Acids	36-51	arachidonate 5-lipoxygenase	Homo sapiens	67-81
3677322-3	1987	However, acetyltransferases have also been shown to catalyze a final metabolic activation step in the conversion of both hydroxamic acid (e.g. N-hydroxy-N-acetyl-2-aminofluorene N,O-acyltransferase) and N-hydroxy-arylamine (e.g. N-hydroxy-2-aminofluorene O-acetyltransferase) metabolites to DNA-bound adducts.	Hydroxamic Acids	121-136	CAS1 domain containing 1	Homo sapiens	255-274
3669019-0	1987	In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.	Hydroxamic Acids	28-43	arachidonate 5-lipoxygenase	Rattus norvegicus	58-72
3820229-1	1987	The hydroxamic acid functionality can be incorporated in a variety of simple molecules to produce potent inhibitors of 5-lipoxygenase.	Hydroxamic Acids	4-19	arachidonate 5-lipoxygenase	Homo sapiens	119-133
3768044-0	1986	Effect of ring substituents on the transketolase-catalyzed conversion of nitroso aromatics to hydroxamic acids.	Hydroxamic Acids	94-110	transketolase	Homo sapiens	35-48
2989266-5	1985	It also hydrolyzes ubiquitin COOH-terminal hydroxamic acid, but is inactivated under the conditions for assaying ubiquitin-hydroxylamine adduct hydrolysis.	Hydroxamic Acids	43-58	ubiquitin	Oryctolagus cuniculus	19-28
3717945-0	1986	Participation of liver aldehyde oxidase in reductive metabolism of hydroxamic acids to amides.	Hydroxamic Acids	67-83	aldehyde oxidase 1	Homo sapiens	23-39
4093520-13	1985	Use of the hydroxamic acid reaction made it possible to estimate the apparent extent of carboxyl modification of beta-lactoglobulin through esterification with methanol, ethanol, and n-butanol.	Hydroxamic Acids	11-26	beta-lactoglobulin	Bos taurus	113-131
2989266-5	1985	It also hydrolyzes ubiquitin COOH-terminal hydroxamic acid, but is inactivated under the conditions for assaying ubiquitin-hydroxylamine adduct hydrolysis.	Hydroxamic Acids	43-58	ubiquitin	Oryctolagus cuniculus	113-122
7192358-8	1980	Apparently, hydroxamic acids can affect the operation of the microsomal monooxigenase system containing cytochrome P-450.	Hydroxamic Acids	12-28	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	104-120
2858339-1	1985	The reaction of bovine (Bos taurus) and porcine (Sus scrufa) cardiac alpha-ketoglutarate dehydrogenase complex (alpha-KGD) with 4-chloronitrosobenzene (I) was shown to produce a hydroxamic acid (IV) and a product due to a Bamberger rearrangement as previously shown for Escherichia coli alpha-KGD.	Hydroxamic Acids	178-193	oxoglutarate dehydrogenase	Bos taurus	69-102
6667545-0	1983	Evidence for reduction of hydroxamic acids to the corresponding amides by liver aldehyde oxidase.	Hydroxamic Acids	26-42	aldehyde oxidase 1	Homo sapiens	80-96
33493830-2	2021	A novel series of hydroxamic acid-containing 4-aminoquinazoline derivatives as irreversible ErbB/HDAC multitargeted inhibitors for NSCLC therapy had been designed and synthesized, which displayed weak anti-proliferative activity in several EGFR wild-type cancer cell lines (NCI-H838, SK-BR-3, A549, A431) yet retained moderate activity to EGFRT790M resistance mutation harboring NCI-H1975 cells.	Hydroxamic Acids	18-33	epidermal growth factor receptor	Homo sapiens	92-96
33744690-2	2021	The consideration of HDAC inhibition as a prudent approach to circumvent the resistance issue in GBM spurred us to pragmatically design and synthesizes hydroxamic acids endowed with CNS penetrating ability.	Hydroxamic Acids	152-168	histone deacetylase 9	Homo sapiens	21-25
5983751-0	1966	[Studies on the reproducibility of the determination of acetylcholinesterase by the hydroxamic acid method.	Hydroxamic Acids	84-99	acetylcholinesterase (Cartwright blood group)	Homo sapiens	56-76
33493830-2	2021	A novel series of hydroxamic acid-containing 4-aminoquinazoline derivatives as irreversible ErbB/HDAC multitargeted inhibitors for NSCLC therapy had been designed and synthesized, which displayed weak anti-proliferative activity in several EGFR wild-type cancer cell lines (NCI-H838, SK-BR-3, A549, A431) yet retained moderate activity to EGFRT790M resistance mutation harboring NCI-H1975 cells.	Hydroxamic Acids	18-33	epidermal growth factor receptor	Homo sapiens	240-244
33493830-2	2021	A novel series of hydroxamic acid-containing 4-aminoquinazoline derivatives as irreversible ErbB/HDAC multitargeted inhibitors for NSCLC therapy had been designed and synthesized, which displayed weak anti-proliferative activity in several EGFR wild-type cancer cell lines (NCI-H838, SK-BR-3, A549, A431) yet retained moderate activity to EGFRT790M resistance mutation harboring NCI-H1975 cells.	Hydroxamic Acids	18-33	epidermal growth factor receptor	Homo sapiens	339-343
33035922-5	2021	However, the hydroxamic acid functional group still represents the predominant zinc-binding group (ZBG), that often suffers from poor pharmacokinetics and mutagenic potential, thus impairing the application of hydroxamate-based HDAC6is for long-term therapies.	Hydroxamic Acids	13-28	histone deacetylase 6	Homo sapiens	228-233
32945135-0	2021	A Structure-Activity Relationship Study of Novel Hydroxamic Acid Inhibitors around the S1 Subsite of Human Aminopeptidase N.	Hydroxamic Acids	49-64	alanyl aminopeptidase, membrane	Homo sapiens	107-123
33433550-0	2021	Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition.	Hydroxamic Acids	30-45	histone deacetylase 9	Homo sapiens	57-76
33433550-0	2021	Antibody drug conjugates with hydroxamic acid cargos for histone deacetylase (HDAC) inhibition.	Hydroxamic Acids	30-45	histone deacetylase 9	Homo sapiens	78-82
33397936-4	2021	Here, we synthesize hydroxamic acid-modified histone peptides and use them in femtomolar microarrays for the direct capture and detection of the four class I HDAC isozymes.	Hydroxamic Acids	20-35	histone deacetylase 9	Homo sapiens	158-162
33397936-6	2021	We conclude that similar hydroxamic acid-modified histone peptide microarrays and libraries could find broad application to identify class I HDAC isozyme-specific substrates and facilitate the development of isozyme-selective HDAC inhibitors and probes.	Hydroxamic Acids	25-40	histone deacetylase 9	Homo sapiens	141-145
33397936-6	2021	We conclude that similar hydroxamic acid-modified histone peptide microarrays and libraries could find broad application to identify class I HDAC isozyme-specific substrates and facilitate the development of isozyme-selective HDAC inhibitors and probes.	Hydroxamic Acids	25-40	histone deacetylase 9	Homo sapiens	226-230
32967084-6	2020	Docking study revealed that the pyrido[3,2-d]pyrimidine framework and hydroxamic acid motif of compound A12 were essential for maintaining the activity of HDAC and Mnk.	Hydroxamic Acids	70-85	histone deacetylase 9	Homo sapiens	155-159
33189849-3	2020	Some HDAC inhibitors such as the hydroxamic acid derivatives vorinostat or panobinostat were already approved for the treatment of hematologic cancer diseases, and are under intensive investigation for their use in solid tumors.	Hydroxamic Acids	33-48	histone deacetylase 9	Homo sapiens	5-9
33126591-2	2020	Herein, three bestatin-based hydroxamic acids (P1, P2 and P3) were designed, synthesized and biologically evaluated to see if they could work as HDAC degrader by recruiting cellular inhibitor of apoptosis protein 1 (cIAP1) E3 ubiquitin ligase.	Hydroxamic Acids	29-45	histone deacetylase 9	Homo sapiens	145-149
33126591-2	2020	Herein, three bestatin-based hydroxamic acids (P1, P2 and P3) were designed, synthesized and biologically evaluated to see if they could work as HDAC degrader by recruiting cellular inhibitor of apoptosis protein 1 (cIAP1) E3 ubiquitin ligase.	Hydroxamic Acids	29-45	baculoviral IAP repeat containing 2	Homo sapiens	173-214
33126591-2	2020	Herein, three bestatin-based hydroxamic acids (P1, P2 and P3) were designed, synthesized and biologically evaluated to see if they could work as HDAC degrader by recruiting cellular inhibitor of apoptosis protein 1 (cIAP1) E3 ubiquitin ligase.	Hydroxamic Acids	29-45	baculoviral IAP repeat containing 2	Homo sapiens	216-221
32768649-4	2020	Herein, the synthesis and evaluation of d-proline-derived hydroxamic acids containing amino appendages at C-4 as gelatinase inhibitors are reported.	Hydroxamic Acids	58-74	complement C4A (Rodgers blood group)	Homo sapiens	106-109
33759126-7	2021	Herein, the design of HDAC6 inhibitors is based on linking the identified fragments with the aliphatic or aromatic linker and hydroxamic acid (ZBG) moiety.	Hydroxamic Acids	126-141	histone deacetylase 6	Homo sapiens	22-27
32679453-6	2020	In the present study, 45 hydroxamic acid derivatives were produced, and compound 26 was screened out as a highly selective Lead compound of Leukotriene A4 Hydrolase (LTA4H), i.e., an enzyme critical to the biosynthesis of LTB4.	Hydroxamic Acids	25-40	leukotriene A4 hydrolase	Mus musculus	140-164
32679453-6	2020	In the present study, 45 hydroxamic acid derivatives were produced, and compound 26 was screened out as a highly selective Lead compound of Leukotriene A4 Hydrolase (LTA4H), i.e., an enzyme critical to the biosynthesis of LTB4.	Hydroxamic Acids	25-40	leukotriene A4 hydrolase	Mus musculus	166-171
32967084-6	2020	Docking study revealed that the pyrido[3,2-d]pyrimidine framework and hydroxamic acid motif of compound A12 were essential for maintaining the activity of HDAC and Mnk.	Hydroxamic Acids	70-85	ATPase copper transporting alpha	Homo sapiens	164-167
31072216-0	2019	Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.	Hydroxamic Acids	39-54	histone deacetylase 6	Homo sapiens	74-79
32591593-0	2020	Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.	Hydroxamic Acids	0-15	histone deacetylase 1	Homo sapiens	31-36
32591593-0	2020	Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.	Hydroxamic Acids	0-15	histone deacetylase 6	Homo sapiens	38-43
32591593-0	2020	Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.	Hydroxamic Acids	0-15	histone deacetylase 8	Homo sapiens	48-53
32153186-0	2020	Discovery of Thieno[2,3-d]pyrimidine-Based Hydroxamic Acid Derivatives as Bromodomain-Containing Protein 4/Histone Deacetylase Dual Inhibitors Induce Autophagic Cell Death in Colorectal Carcinoma Cells.	Hydroxamic Acids	43-58	bromodomain containing 4	Rattus norvegicus	74-106
32153186-2	2020	Based on the integrated fragment-based drug design, synthesis, and in vitro and in vivo evaluations, a series of novel thieno[2,3-d]pyrimidine-based hydroxamic acid derivatives are discovered as selective BRD4-HDAC dual inhibitors.	Hydroxamic Acids	149-164	bromodomain containing 4	Rattus norvegicus	205-209
31904962-18	2020	We propose that the PCET reactions of hydroxamic acids are mediated by a hydrogen-bonded proton wire in the beta2 subunit.	Hydroxamic Acids	38-54	glycoprotein hormone subunit alpha 2	Homo sapiens	108-113
31915112-4	2020	In addition, compounds having hydroxamic acid (15a-b) or carboxylic acid (16a-b) functionalities resulted in greater selectivity ratios for CA IX/XII over CAI/II in the range of 4.1-121.5 although with KI values in lower micromolar potency (KIs = 0.36-0.85 muM for CA IX/XII).	Hydroxamic Acids	30-45	carbonic anhydrase 9	Homo sapiens	140-145
31915112-4	2020	In addition, compounds having hydroxamic acid (15a-b) or carboxylic acid (16a-b) functionalities resulted in greater selectivity ratios for CA IX/XII over CAI/II in the range of 4.1-121.5 although with KI values in lower micromolar potency (KIs = 0.36-0.85 muM for CA IX/XII).	Hydroxamic Acids	30-45	carbonic anhydrase 3	Homo sapiens	155-161
31915112-4	2020	In addition, compounds having hydroxamic acid (15a-b) or carboxylic acid (16a-b) functionalities resulted in greater selectivity ratios for CA IX/XII over CAI/II in the range of 4.1-121.5 although with KI values in lower micromolar potency (KIs = 0.36-0.85 muM for CA IX/XII).	Hydroxamic Acids	30-45	carbonic anhydrase 9	Homo sapiens	265-270
30332940-6	2020	In this review, we summarize four major structural classes of HDAC inhibitors (hydroxamic acid derivatives, aminobenzamide, cyclic peptide and short-chain fatty acids) that are in clinical trials and different computer modeling tools available for their structural modifications as a guide to discover additional HDAC inhibitors with greater therapeutic utility.	Hydroxamic Acids	79-94	histone deacetylase 9	Homo sapiens	62-66
30633630-3	2020	This work attempts to explore the structural basis of selective HDAC8 inhibition by docking, pharmacophore and 3 D QSAR studies of 53 highly potent and highly selective triazol-based hydroxamic acid inhibitors.	Hydroxamic Acids	183-198	histone deacetylase 8	Homo sapiens	64-69
31714079-0	2020	Virtual Screening Approach for the Identification of Hydroxamic Acids as Novel Human Ecto-5"-Nucleotidase Inhibitors.	Hydroxamic Acids	53-69	5'-nucleotidase ecto	Homo sapiens	85-105
31714079-4	2020	Here, we aimed to search for hydroxamic acid-containing compounds as potential human ecto-5"-NT inhibitors, since this group is known to be a strong zinc chelator.	Hydroxamic Acids	29-44	5'-nucleotidase ecto	Homo sapiens	85-95
31714079-10	2020	Furthermore, to the best of our knowledge, they are the first hydroxamic acid-containing inhibitors of human ecto-5"-NT described so far.	Hydroxamic Acids	62-77	5'-nucleotidase ecto	Homo sapiens	109-119
31675511-0	2020	6-Methyluracil derivatives as peripheral site ligand-hydroxamic acid conjugates: Reactivation for paraoxon-inhibited acetylcholinesterase.	Hydroxamic Acids	53-68	acetylcholinesterase (Cartwright blood group)	Homo sapiens	117-137
31675511-2	2020	Using paraoxon (POX) as a model organophosphate, it was shown that 6-methyluracil derivatives linked with hydroxamic acid are able to reactivate POX-inhibited human acetylcholinesterase (AChE) in vitro.	Hydroxamic Acids	106-121	acetylcholinesterase (Cartwright blood group)	Homo sapiens	165-185
31675511-2	2020	Using paraoxon (POX) as a model organophosphate, it was shown that 6-methyluracil derivatives linked with hydroxamic acid are able to reactivate POX-inhibited human acetylcholinesterase (AChE) in vitro.	Hydroxamic Acids	106-121	acetylcholinesterase (Cartwright blood group)	Homo sapiens	187-191
31072216-3	2019	Thus, new class of hydroxamic acid-based derivatives were designed on structural basis to perform preferential activity against HDAC6 targeting solid tumours.	Hydroxamic Acids	19-34	histone deacetylase 6	Homo sapiens	128-133
31420257-4	2019	Three novel fluorescent HDAC inhibitors were synthesized utilizing efficient submonomer protocols followed by the introduction of a hydroxamic acid or 2-aminoanilide moiety as zinc-binding group.	Hydroxamic Acids	132-147	histone deacetylase 9	Homo sapiens	24-28
31400937-0	2019	Exploring hydroxamic acid inhibitors of HDAC1 and HDAC2 using small molecule tools and molecular or homology modelling.	Hydroxamic Acids	10-25	histone deacetylase 1	Homo sapiens	40-45
31400937-0	2019	Exploring hydroxamic acid inhibitors of HDAC1 and HDAC2 using small molecule tools and molecular or homology modelling.	Hydroxamic Acids	10-25	histone deacetylase 2	Homo sapiens	50-55
31251594-2	2019	We have previously identified hydroxamic acid-containing analogues that are potent inhibitors of the APN homologue from the malarial parasite Plasmodium falciparum M1 aminopeptidase (PfA-M1).	Hydroxamic Acids	30-45	alanyl aminopeptidase, membrane	Homo sapiens	101-104
31177073-0	2019	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.	Hydroxamic Acids	41-56	histone deacetylase 9	Homo sapiens	72-91
31330099-4	2019	Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect.	Hydroxamic Acids	0-15	histone deacetylase 1	Homo sapiens	36-45
31330099-4	2019	Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect.	Hydroxamic Acids	0-15	granulin precursor	Homo sapiens	130-134
31330099-4	2019	Hydroxamic-acid-based inhibitors of HDACs 1-3, reported to have fast-on/fast-off binding kinetics, induce increased expression of PGRN in human neuronal models, while the benzamide class of slow-binding HDAC inhibitors does not produce this effect.	Hydroxamic Acids	0-15	histone deacetylase 9	Homo sapiens	36-40
31330099-7	2019	We provide evidence that two prototypical, potent hydroxamic acid HDAC inhibitors that induce PGRN (panobinostat and trichostatin A) exhibit an initial fast-binding step followed by a second, slower step, referred to as mechanism B of slow binding, rather than simpler fast-on/fast-off binding kinetics.	Hydroxamic Acids	50-65	histone deacetylase 9	Homo sapiens	66-70
31330099-7	2019	We provide evidence that two prototypical, potent hydroxamic acid HDAC inhibitors that induce PGRN (panobinostat and trichostatin A) exhibit an initial fast-binding step followed by a second, slower step, referred to as mechanism B of slow binding, rather than simpler fast-on/fast-off binding kinetics.	Hydroxamic Acids	50-65	granulin precursor	Homo sapiens	94-98
31251594-4	2019	A series of novel hydroxamic acid analogues were developed using a structure-based design approach and evaluated their inhibition activities against APN.	Hydroxamic Acids	18-33	alanyl aminopeptidase, membrane	Homo sapiens	149-152
31120744-0	2019	Hydroxamic Acid Derivatives of beta-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.	Hydroxamic Acids	0-15	AKT serine/threonine kinase 1	Homo sapiens	125-128
31120744-0	2019	Hydroxamic Acid Derivatives of beta-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways.	Hydroxamic Acids	0-15	mechanistic target of rapamycin kinase	Homo sapiens	129-133
31312074-0	2019	Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors.	Hydroxamic Acids	40-56	histone deacetylase 2	Homo sapiens	60-65
30629434-1	2019	In the present study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors were designed and synthesized using pyrimidine-pyrazolyl pharmacophore to append HDAC recognition cap and hydroxamic acid as a zinc-binding motif.	Hydroxamic Acids	237-252	histone deacetylase 9	Homo sapiens	73-77
30629434-1	2019	In the present study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors were designed and synthesized using pyrimidine-pyrazolyl pharmacophore to append HDAC recognition cap and hydroxamic acid as a zinc-binding motif.	Hydroxamic Acids	237-252	mechanistic target of rapamycin kinase	Homo sapiens	83-112
30629434-1	2019	In the present study, a series of novel dual-target histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors were designed and synthesized using pyrimidine-pyrazolyl pharmacophore to append HDAC recognition cap and hydroxamic acid as a zinc-binding motif.	Hydroxamic Acids	237-252	mechanistic target of rapamycin kinase	Homo sapiens	114-118
29732991-0	2019	Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.	Hydroxamic Acids	18-33	histone deacetylase 1	Homo sapiens	50-55
29732991-3	2019	METHODS: The present research work comprises atom-based 3D-QSAR, docking, molecular dynamic simulations and DFT (density functional theory) studies on a diverse series of hydroxamic acid derivatives as selective HDAC1 inhibitors.	Hydroxamic Acids	171-186	histone deacetylase 1	Homo sapiens	212-217
29674965-8	2018	This is the first demonstration that imidazole and thiazole carboxylic acid-based compounds are more efficacious MMP-2 inhibitor than their hydroxamic acid derivatives.	Hydroxamic Acids	140-155	matrix metallopeptidase 2	Rattus norvegicus	113-118
29852860-4	2019	Methodology and Result: Several research articles spanning between 2016 and 2017 were reviewed in this article and presently offer critical insights into the important strategies such as structure-based rational drug design, multi-parameter lead optimization methodologies, relevant SAR studies and biology of various class of HDAC inhibitors, such as hydroxamic acids, benzamides, cyclic peptides, aliphatic acids, summarising the clinical trials and results of various combination drug therapy till date.	Hydroxamic Acids	352-368	histone deacetylase 9	Homo sapiens	327-331
29620892-4	2018	We have developed a novel class of ATX inhibitors containing the zinc binding functionality of hydroxamic acid.	Hydroxamic Acids	95-110	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	35-38
29620892-5	2018	Such novel hydroxamic acids that incorporate a non-natural delta-amino acid residue exhibit high in vitro inhibitory potency over ATX (IC50 values 50-60 nM).	Hydroxamic Acids	11-27	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	130-133
29932631-4	2018	Consistent with a model of active site Zn2+ chelation by the carboxylic acid present in tianeptine, newly synthesized analogues containing either a hydroxamic acid or ortho-aminoanilide exhibited increased potency and selectivity among the HDAC family.	Hydroxamic Acids	148-163	histone deacetylase 9	Homo sapiens	240-244
29500130-0	2018	Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.	Hydroxamic Acids	53-68	histone deacetylase 6	Homo sapiens	75-96
29500130-3	2018	A series of hydroxamic acid derivatives bearing phenylpyrazol moiety were designed and synthesized as HDAC6 inhibitors.	Hydroxamic Acids	12-27	histone deacetylase 6	Homo sapiens	102-107
29620892-0	2018	Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.	Hydroxamic Acids	0-16	ectonucleotide pyrophosphatase/phosphodiesterase 2	Mus musculus	45-54
29807520-0	2018	Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.	Hydroxamic Acids	6-22	sarcosine dehydrogenase	Homo sapiens	139-142
29377564-0	2018	Design, Synthesis, and Biological Evaluation of Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.	Hydroxamic Acids	65-80	alanyl aminopeptidase, membrane	Homo sapiens	96-112
29377564-0	2018	Design, Synthesis, and Biological Evaluation of Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.	Hydroxamic Acids	65-80	alanyl aminopeptidase, membrane	Homo sapiens	114-117
29106445-0	2018	A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.	Hydroxamic Acids	9-24	histone deacetylase 6	Sus scrofa	86-91
29393896-1	2018	We designed and synthesized carbamates of the clinically-approved HDAC (histone deacetylase) inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in order to validate our previously-proposed hypothesis that these carbamates might serve as prodrugs for hydroxamic acid containing HDAC inhibitors.	Hydroxamic Acids	131-146	histone deacetylase 9	Homo sapiens	66-70
29393896-1	2018	We designed and synthesized carbamates of the clinically-approved HDAC (histone deacetylase) inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in order to validate our previously-proposed hypothesis that these carbamates might serve as prodrugs for hydroxamic acid containing HDAC inhibitors.	Hydroxamic Acids	131-146	histone deacetylase 9	Homo sapiens	72-91
29607910-4	2018	Molecular docking study revealed that the conformation of 7m" in the active site of HDAC2 was similar to positive drug SAHA, which were oriented with the hydroxamic acid towards the catalytic center and formed metal binding with zinc ion.	Hydroxamic Acids	154-169	histone deacetylase 2	Homo sapiens	84-89
29133060-5	2018	Based on their different zinc binding groups (ZBGs), in this review, HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur containing ZBG based derivatives and other ZBG-derived compounds, and their enzymatic inhibitory activity, selectivity and other biological activities are introduced and summarized.	Hydroxamic Acids	101-117	histone deacetylase 6	Homo sapiens	69-74
28888950-3	2017	AOX is also reported to catalyze the reductive metabolism of nitro-compounds, N-oxides, sulfoxides, isoxazoles, isothiazoles, nitrite and hydroxamic acids.	Hydroxamic Acids	138-154	aldehyde oxidase 1	Homo sapiens	0-3
28746804-0	2017	A Linker for the Solid-Phase Synthesis of Hydroxamic Acids and Identification of HDAC6 Inhibitors.	Hydroxamic Acids	42-58	histone deacetylase 6	Homo sapiens	81-86
28632338-1	2017	The relevance of the -CF2 H moiety has attracted considerable attention from organic synthetic and medicinal chemistry communities, because this group can act as a more lipophilic isostere of the carbinol, thiol, hydroxamic acid, or amide groups.	Hydroxamic Acids	213-228	ATPase H+ transporting accessory protein 1	Homo sapiens	22-25
28419930-0	2017	Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.	Hydroxamic Acids	57-72	DNA methyltransferase 1	Homo sapiens	88-92
28722301-4	2017	The zinc-binding MMP-13 inhibitors contain a small set of zinc-binding groups (ZBGs), including hydroxamic acid, pyrimidinetrione, reversed hydroxamic acid and hydantoin, carboxylic acid, 1,2,4,-triazole, and 1,2,4,-triazolone.	Hydroxamic Acids	96-111	matrix metallopeptidase 13	Homo sapiens	17-23
28722301-4	2017	The zinc-binding MMP-13 inhibitors contain a small set of zinc-binding groups (ZBGs), including hydroxamic acid, pyrimidinetrione, reversed hydroxamic acid and hydantoin, carboxylic acid, 1,2,4,-triazole, and 1,2,4,-triazolone.	Hydroxamic Acids	140-155	matrix metallopeptidase 13	Homo sapiens	17-23
28601509-3	2017	Herein, based on rational drug design strategy, hydroxamic acid derivatives of olaparib were constructed as dual PARP and HDAC inhibitors.	Hydroxamic Acids	48-63	poly(ADP-ribose) polymerase 1	Homo sapiens	113-117
28419930-3	2017	Based on the structure of DNMT inhibitor NSC-319745 and the pharmacophore characteristics of HDAC inhibitors, a series of hydroxamic acid derivatives of NSC-319745 were designed and synthesized as DNMT and HDAC multifunctional inhibitors.	Hydroxamic Acids	122-137	DNA methyltransferase 1	Homo sapiens	26-30
28419930-3	2017	Based on the structure of DNMT inhibitor NSC-319745 and the pharmacophore characteristics of HDAC inhibitors, a series of hydroxamic acid derivatives of NSC-319745 were designed and synthesized as DNMT and HDAC multifunctional inhibitors.	Hydroxamic Acids	122-137	DNA methyltransferase 1	Homo sapiens	197-201
27759399-0	2016	Metal-Free Direct Amidation of Naphthoquinones Using Hydroxamic Acids as an Amide Source: Application in the Synthesis of an HDAC6 Inhibitor.	Hydroxamic Acids	53-69	histone deacetylase 6	Homo sapiens	125-130
27542739-2	2016	Matrix metalloproteinases (MMPs) can be inhibited by a multitude of compounds, including hydroxamic acids.	Hydroxamic Acids	89-105	matrix metallopeptidase 13	Homo sapiens	27-31
27624080-0	2016	LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.	Hydroxamic Acids	61-77	solute carrier family 7 member 5	Homo sapiens	0-4
24020585-5	2014	Docking studies revealed that these hydroxamic acid displayed higher affinities than SAHA toward HDAC8.	Hydroxamic Acids	36-51	histone deacetylase 8	Homo sapiens	97-102
26510381-3	2016	In this study, we have selected hydroxamic acid derivatives as HDACi and performed fragment-based G-QSAR, molecular docking studies and molecular dynamics simulations for elucidating the dynamic mode of action of HDACi with His-Asp catalytic dyad of HDAC4.	Hydroxamic Acids	32-47	histone deacetylase 4	Homo sapiens	250-255
27374062-0	2016	Structure of "linkerless" hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.	Hydroxamic Acids	26-41	histone deacetylase 8	Homo sapiens	52-57
27250035-3	2016	In the present study, we found that in cells, both endogenous and exogenous Osx protein increased after treatment with histone deacetylase inhibitors Trichostatin A and hydroxamic acid.	Hydroxamic Acids	169-184	Sp7 transcription factor 7	Mus musculus	76-79
27074627-2	2016	Here we report synthesis, structural characterization, and biological activity of new hydroxamic acid-based inhibitors with nanomolar affinity for human GCPII.	Hydroxamic Acids	86-101	folate hydrolase 1	Homo sapiens	153-158
26475519-0	2015	Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.	Hydroxamic Acids	38-53	kinase insert domain receptor	Homo sapiens	76-121
26475519-0	2015	Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.	Hydroxamic Acids	38-53	histone deacetylase 9	Homo sapiens	126-145
26475519-1	2015	A series of hybrids derived from 4-anilinoquinazoline and hydroxamic acid were designed, synthesized, and evaluated as dual inhibitors of vascular endothelia growth factor receptor-2 (VEGFR-2) tyrosine kinase and histone deacetylase (HDAC).	Hydroxamic Acids	58-73	kinase insert domain receptor	Homo sapiens	138-182
26475519-1	2015	A series of hybrids derived from 4-anilinoquinazoline and hydroxamic acid were designed, synthesized, and evaluated as dual inhibitors of vascular endothelia growth factor receptor-2 (VEGFR-2) tyrosine kinase and histone deacetylase (HDAC).	Hydroxamic Acids	58-73	kinase insert domain receptor	Homo sapiens	184-191
26475519-1	2015	A series of hybrids derived from 4-anilinoquinazoline and hydroxamic acid were designed, synthesized, and evaluated as dual inhibitors of vascular endothelia growth factor receptor-2 (VEGFR-2) tyrosine kinase and histone deacetylase (HDAC).	Hydroxamic Acids	58-73	histone deacetylase 9	Homo sapiens	213-232
25882299-0	2015	Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.	Hydroxamic Acids	44-59	histone deacetylase 9	Homo sapiens	94-113
25882299-0	2015	Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.	Hydroxamic Acids	44-59	histone deacetylase 9	Homo sapiens	115-119
25311567-1	2014	A series of 1,3,4-thiadiazole-containing hydroxamic acids, in accord with the common pharmacophore of histone deacetylase (HDAC) inhibitors (a Zn(2+) binding moiety-a linker-a surface recognition motif), was identified as submicromolar HDAC inhibitors by our group.	Hydroxamic Acids	41-57	histone deacetylase 9	Homo sapiens	102-121
25311567-1	2014	A series of 1,3,4-thiadiazole-containing hydroxamic acids, in accord with the common pharmacophore of histone deacetylase (HDAC) inhibitors (a Zn(2+) binding moiety-a linker-a surface recognition motif), was identified as submicromolar HDAC inhibitors by our group.	Hydroxamic Acids	41-57	histone deacetylase 9	Homo sapiens	123-127
26741358-2	2016	In this work, a series of hybrids bearing N-phenylquinazolin-4-amine and hydroxamic acid moieties were designed and identified as dual VEGFR-2/HDAC inhibitors.	Hydroxamic Acids	73-88	kinase insert domain receptor	Homo sapiens	135-142
26555243-0	2015	Novel beta-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.	Hydroxamic Acids	21-36	tumor protein p53	Homo sapiens	143-146
26061299-0	2015	Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-alpha converting enzyme as potential therapeutics for hepatitis.	Hydroxamic Acids	43-58	ADAM metallopeptidase domain 17	Homo sapiens	80-125
26061299-4	2015	Subsequently, the INN molecular structure was simplified to a chemical sketch of peptide hydroxamic acid compound, which can be regarded as a linear tripeptide capped by a N-terminal carboxybenzyl group (chemically protective group) and a C-terminal hydroxamate moiety (coordinated to the Zn(2+) at TACE active site).	Hydroxamic Acids	89-104	ADAM metallopeptidase domain 17	Homo sapiens	299-303
25937017-4	2015	Both classes of hydroxamic acids caused hyperacetylation of alpha-tubulin pointing to inhibition of histone deacetylase 6 (HDAC6) as part of their antiviral activity.	Hydroxamic Acids	16-32	histone deacetylase 6	Homo sapiens	100-121
25937017-4	2015	Both classes of hydroxamic acids caused hyperacetylation of alpha-tubulin pointing to inhibition of histone deacetylase 6 (HDAC6) as part of their antiviral activity.	Hydroxamic Acids	16-32	histone deacetylase 6	Homo sapiens	123-128
25800440-3	2015	By monitoring spectral counts of specific hydroxamic acid signatures generated after the conversion of the ADP-ribose modification onto peptides by hydroxylamine hydrolysis, we undertook a thorough mass spectrometry mapping of the glutamate and aspartate ADP-ribosylation sites onto automodified PARP-1, PARP-2 and PARP-3.	Hydroxamic Acids	42-57	poly(ADP-ribose) polymerase 1	Homo sapiens	296-302
25800440-3	2015	By monitoring spectral counts of specific hydroxamic acid signatures generated after the conversion of the ADP-ribose modification onto peptides by hydroxylamine hydrolysis, we undertook a thorough mass spectrometry mapping of the glutamate and aspartate ADP-ribosylation sites onto automodified PARP-1, PARP-2 and PARP-3.	Hydroxamic Acids	42-57	poly(ADP-ribose) polymerase 2	Homo sapiens	304-310
25800440-3	2015	By monitoring spectral counts of specific hydroxamic acid signatures generated after the conversion of the ADP-ribose modification onto peptides by hydroxylamine hydrolysis, we undertook a thorough mass spectrometry mapping of the glutamate and aspartate ADP-ribosylation sites onto automodified PARP-1, PARP-2 and PARP-3.	Hydroxamic Acids	42-57	poly(ADP-ribose) polymerase family member 3	Homo sapiens	315-321
25591587-2	2015	In previous study, a novel hydroxamic acid derivate, CTS203 (cyclo(-l-Asu(NHOH)-l-A3mc6c-l-Phe-d-Pro-)), demonstrated promising HDAC inhibitory activity.	Hydroxamic Acids	27-42	histone deacetylase 9	Homo sapiens	128-132
24993024-0	2014	Substitution of a hydroxamic acid anchor into the MK-2 dye for enhanced photovoltaic performance and water stability in a DSSC.	Hydroxamic Acids	18-33	MAPK activated protein kinase 2	Homo sapiens	50-54
24888409-6	2014	In conclusion, the ligand flexibility, molecular weight and chemical moieties (hydroxamic acid, aryl and aliphatic moieties) are the principal properties required to increase the binding affinity on HDAC8.	Hydroxamic Acids	79-94	histone deacetylase 8	Homo sapiens	199-204
21937229-0	2011	Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.	Hydroxamic Acids	55-70	matrix metallopeptidase 13	Homo sapiens	85-112
24190633-0	2014	A novel hydroxamic acid derivative, MHY218, induces apoptosis and cell cycle arrest through downregulation of NF-kappaB in HCT116 human colon cancer cells.	Hydroxamic Acids	8-23	nuclear factor kappa B subunit 1	Homo sapiens	110-119
24380043-0	2013	Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.	Hydroxamic Acids	37-52	histone deacetylase 9	Homo sapiens	99-118
24380043-0	2013	Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.	Hydroxamic Acids	37-52	histone deacetylase 9	Homo sapiens	120-124
24380043-1	2013	Hydroxamic acid-based histone deacetylase inhibitors (HDACis) are a class of molecules with therapeutic potential currently reflected in the use of suberoylanilide hydroxamic acid (SAHA; Vorinostat) to treat cutaneous T-cell lymphomas (CTCL).	Hydroxamic Acids	0-15	histone deacetylase 9	Homo sapiens	22-41
24023063-3	2013	Here, we show that a hydroxamic acid-based small-molecule N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-oxoethyl)benzamide (HPOB) selectively inhibits HDAC6 catalytic activity in vivo and in vitro.	Hydroxamic Acids	21-36	histone deacetylase 6	Homo sapiens	154-159
22877822-5	2012	As a proof of concept, we employed a CDy1-based screening in 384 well-plates to examine the effect of newly synthesized hydroxamic acid derivatives in reprogramming mouse fibroblasts transduced with Oct4, Sox2 and Klf-4 without c-Myc.	Hydroxamic Acids	120-135	POU domain, class 5, transcription factor 1, related sequence 1	Mus musculus	199-203
22684055-2	2012	Therefore, the catalytic domain of human ADAM-8 was expressed, purified and crystallized in complex with a hydroxamic acid inhibitor, batimastat.	Hydroxamic Acids	107-122	ADAM metallopeptidase domain 8	Homo sapiens	41-47
22973455-3	2012	These studies" authors have proposed that the unique action of these compounds compared to hydroxamic acid-based HDAC inhibitors results from their unusual slow-on/slow-off kinetics of binding, preferentially to HDAC3, resulting in a distinctive pharmacological profile and reduced toxicity.	Hydroxamic Acids	91-106	histone deacetylase 3	Mus musculus	212-217
24565573-6	2014	Moreover, a derivative bearing a hydroxamic acid residue bound to C-3 amide portion was found to inhibit both Hsp90 and HDAC6.	Hydroxamic Acids	33-48	heat shock protein 90 alpha family class A member 1	Homo sapiens	110-115
24565573-6	2014	Moreover, a derivative bearing a hydroxamic acid residue bound to C-3 amide portion was found to inhibit both Hsp90 and HDAC6.	Hydroxamic Acids	33-48	histone deacetylase 6	Homo sapiens	120-125
24562770-4	2014	We show that the investigational drug MLN0128, which inhibits both complexes of mTOR (mTORC1 and mTORC2), and the hydroxamic acid pan-HDAC inhibitor TSA synergistically inhibit the viability of a phenotypically diverse panel of five breast cancer cell lines (HR-/+, HER2-/+).	Hydroxamic Acids	114-129	nuclear receptor subfamily 4 group A member 1	Homo sapiens	259-261
24562770-4	2014	We show that the investigational drug MLN0128, which inhibits both complexes of mTOR (mTORC1 and mTORC2), and the hydroxamic acid pan-HDAC inhibitor TSA synergistically inhibit the viability of a phenotypically diverse panel of five breast cancer cell lines (HR-/+, HER2-/+).	Hydroxamic Acids	114-129	erb-b2 receptor tyrosine kinase 2	Homo sapiens	266-270
25335884-0	2014	8-Hydroxyquinoline and hydroxamic acid inhibitors of botulinum neurotoxin BoNT/A.	Hydroxamic Acids	23-38	neurotoxin	Clostridium botulinum	63-73
23368884-1	2013	Hydroxamic acids were designed, synthesized, and evaluated for their ability to selectively inhibit human histone deacetylase 6 (HDAC6).	Hydroxamic Acids	0-16	histone deacetylase 6	Homo sapiens	106-127
23368884-1	2013	Hydroxamic acids were designed, synthesized, and evaluated for their ability to selectively inhibit human histone deacetylase 6 (HDAC6).	Hydroxamic Acids	0-16	histone deacetylase 6	Homo sapiens	129-134
22048700-0	2011	Design, synthesis and biological evaluation of hydroxamic acid derivatives as potential high density lipoprotein (HDL) receptor CLA-1 up-regulating agents.	Hydroxamic Acids	47-62	scavenger receptor class B member 1	Homo sapiens	128-133
21937229-3	2011	Our efforts have resulted in the discovery of a series of hydroxamic acid inhibitors of MMP-13 that do not significantly inhibit MMP-2 (gelatinase-1).	Hydroxamic Acids	58-73	matrix metallopeptidase 13	Homo sapiens	88-94
21924799-4	2011	Up to now, few hydroxamic acid derivatives with linear linker were reported to possess HDAC8 selectivity over HDAC1.	Hydroxamic Acids	15-30	histone deacetylase 8	Homo sapiens	87-92
21924799-4	2011	Up to now, few hydroxamic acid derivatives with linear linker were reported to possess HDAC8 selectivity over HDAC1.	Hydroxamic Acids	15-30	histone deacetylase 1	Homo sapiens	110-115
21718944-11	2011	The study at hand, however, does present a number of lessons critical to both the synthesis of hydroxamic acid containing PET radiotracers and imaging agents aimed at delineating HDAC expression.	Hydroxamic Acids	95-110	histone deacetylase 9	Homo sapiens	179-183
21840713-3	2011	Hydroxamic acid (NHOH) is a well-known metal chelator, potentially having both tyrosinase inhibitory activity and free radical scavenging activity.	Hydroxamic Acids	0-15	tyrosinase	Mus musculus	79-89
21376605-3	2011	Recently, we published a series of hydroxamic acid derivatives of glycyrrhetinic acid showing high selectivity for 11beta-HSD2.	Hydroxamic Acids	35-50	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	115-126
21493063-1	2011	Continuing our interest in designing compounds preferentially potent and selective for MMP-13, we report on a series of hydroxamic acids with a flexible amide P1" substituents.	Hydroxamic Acids	120-136	matrix metallopeptidase 13	Homo sapiens	87-93
21456530-3	2011	Using Born-Oppenheimer ab initio QM/MM MD simulations, a state-of-the-art approach to simulating metallo-enzymes, we have found that the hydroxamic acid remains to be protonated upon its binding to HDAC8, and thus disproved the mechanistic hypothesis that the distinct zinc-hydroxamate chelation modes between two HDAC subclasses come from different protonation states of the hydroxamic acid.	Hydroxamic Acids	137-152	histone deacetylase 8	Homo sapiens	198-203
20801552-4	2010	Our findings demonstrate that the newly synthesized hydroxamic acid derivative of sulindac and its sulfone and sulfide metabolites were characterized by a good anticancer activity on human pancreatic and colon cancer cells, both in terms of potency (IC(50) mean values from 6 +- 1.1 muM to 64 +- 1.1 muM) and efficacy (E(max) of ~100%).	Hydroxamic Acids	52-67	latexin	Homo sapiens	283-286
20855208-3	2010	Numerous, structurally diverse, hydroxamic acid derivative, HDAC inhibitors have been reported and have been shown to induce growth arrest, differentiation, autophagy, and/or apoptotic cell death by inhibiting multiple signaling pathways in cancer cells.	Hydroxamic Acids	32-47	histone deacetylase 9	Homo sapiens	60-64
20851614-5	2010	Several hydroxamic acid derivatives showed high selectivity for 11beta-HSD2.	Hydroxamic Acids	8-23	hydroxysteroid 11-beta dehydrogenase 2	Homo sapiens	64-75
20934292-4	2011	Thermal decomposition involving the hydroxamic acid functional group was suspected and further evaluated using various analytical techniques including reversed-phase HPLC, LC-MS-MS, TGA-FTIR and NMR.	Hydroxamic Acids	36-51	T-box transcription factor 1	Homo sapiens	182-185
22125384-4	2011	120 hydroxamic acid derivatives were designed as inhibitors based on hydrophobic pocket and the Zn (II) catalytic site of HDAC8 active site using Structure Based Drug Design (SBDD) approach.	Hydroxamic Acids	4-19	histone deacetylase 8	Homo sapiens	122-127
21110829-5	2011	Two of them, the hydroxamic acid (SAHA) and Romidepsin (FK 228), are approved in the second line treatment of refractory, persistent or relapsed Cutaneous T Cell Lymphoma (CTCL).	Hydroxamic Acids	17-32	TSPY like 2	Homo sapiens	172-176
20801552-4	2010	Our findings demonstrate that the newly synthesized hydroxamic acid derivative of sulindac and its sulfone and sulfide metabolites were characterized by a good anticancer activity on human pancreatic and colon cancer cells, both in terms of potency (IC(50) mean values from 6 +- 1.1 muM to 64 +- 1.1 muM) and efficacy (E(max) of ~100%).	Hydroxamic Acids	52-67	latexin	Homo sapiens	300-303
20801552-5	2010	Hydroxamic acid derivatives trigger a higher degree of apoptosis than carboxylic acid counterparts, increase bax/bcl-2 expression ratio and induce caspase 3/7 activation.	Hydroxamic Acids	0-15	BCL2 associated X, apoptosis regulator	Homo sapiens	109-112
20801552-5	2010	Hydroxamic acid derivatives trigger a higher degree of apoptosis than carboxylic acid counterparts, increase bax/bcl-2 expression ratio and induce caspase 3/7 activation.	Hydroxamic Acids	0-15	BCL2 apoptosis regulator	Homo sapiens	113-118
20801552-5	2010	Hydroxamic acid derivatives trigger a higher degree of apoptosis than carboxylic acid counterparts, increase bax/bcl-2 expression ratio and induce caspase 3/7 activation.	Hydroxamic Acids	0-15	caspase 3	Homo sapiens	147-156
21874153-1	2010	Carboxylic acids with known central nervous system and histone deacetylase (HDAC) inhibitory activities were converted to hydroxamic acids and tested using a suite of in vitro biochemical assays with recombinant HDAC isoforms, cell based assays in human cervical carcinoma Hela cells and primary cultures from mouse forebrain, and a whole animal (Xenopus laevis) developmental assay.	Hydroxamic Acids	122-138	histone deacetylase 9	Homo sapiens	55-74
21874153-1	2010	Carboxylic acids with known central nervous system and histone deacetylase (HDAC) inhibitory activities were converted to hydroxamic acids and tested using a suite of in vitro biochemical assays with recombinant HDAC isoforms, cell based assays in human cervical carcinoma Hela cells and primary cultures from mouse forebrain, and a whole animal (Xenopus laevis) developmental assay.	Hydroxamic Acids	122-138	histone deacetylase 9	Homo sapiens	76-80
21874153-1	2010	Carboxylic acids with known central nervous system and histone deacetylase (HDAC) inhibitory activities were converted to hydroxamic acids and tested using a suite of in vitro biochemical assays with recombinant HDAC isoforms, cell based assays in human cervical carcinoma Hela cells and primary cultures from mouse forebrain, and a whole animal (Xenopus laevis) developmental assay.	Hydroxamic Acids	122-138	histone deacetylase 9	Homo sapiens	212-216
19682743-2	2010	JNJ-26481585 is a hydroxamic acid derivative, second-generation pan-HDAC inhibitor that has demonstrated high potency in preclinical studies.	Hydroxamic Acids	18-33	histone deacetylase 9	Homo sapiens	68-72
20498699-4	2010	METHODOLOGY/PRINCIPAL FINDINGS: We used a rational design approach based on analysis of combinatorial peptide mixtures and focused compound libraries to develop novel peptide hydroxamic acid inhibitors of IDE.	Hydroxamic Acids	175-190	insulin degrading enzyme	Homo sapiens	205-208
20448342-3	2010	This article reports anti-cancer effects of a hydroxamic acid derivative 24F that was newly-synthesized as an APN inhibitor.	Hydroxamic Acids	46-61	alanyl aminopeptidase, membrane	Homo sapiens	110-113
19565489-9	2009	RESULTS: A number of non-hydroxamic acid-containing compounds that showed a high degree of potency for MMP-13 and selectivity against other MMPs were designed and synthesized.	Hydroxamic Acids	25-40	matrix metallopeptidase 13	Rattus norvegicus	103-109
19791805-0	2009	Hydroxamic acids as a novel family of serine racemase inhibitors: mechanistic analysis reveals different modes of interaction with the pyridoxal-5"-phosphate cofactor.	Hydroxamic Acids	0-16	serine racemase	Homo sapiens	38-53
19947584-0	2009	Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.	Hydroxamic Acids	11-27	histone deacetylase 1	Homo sapiens	33-38
19947584-0	2009	Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.	Hydroxamic Acids	11-27	histone deacetylase 8	Homo sapiens	43-48
19565489-9	2009	RESULTS: A number of non-hydroxamic acid-containing compounds that showed a high degree of potency for MMP-13 and selectivity against other MMPs were designed and synthesized.	Hydroxamic Acids	25-40	matrix metallopeptidase 13	Rattus norvegicus	140-144
19147221-2	2009	The microspheres were designed to selectively bind MMPs from solutions on contact through a direct interaction between the polymer-bound hydroxamic acid groups and the characteristic catalytic site zinc atom common to all MMPs.	Hydroxamic Acids	137-152	matrix metallopeptidase 2	Homo sapiens	51-55
19374404-2	2009	Hydroxamic acids based on CGS27023A or CGS25966 are nonpeptidyl lead structures that specifically target activated MMPs in vivo.	Hydroxamic Acids	0-16	matrix metallopeptidase 2	Homo sapiens	115-119
19410459-2	2009	Many of the known HDAC inhibitors (HDACi) that are in clinical trials possess a hydroxamic acid, that is a strong Zn(2+) binding group, thereby inhibiting some of the class I and class II isoforms.	Hydroxamic Acids	80-95	histone deacetylase 9	Homo sapiens	18-22
18673170-2	2008	This overview describes the chemistry and preliminary characterization of recently disclosed molecules in three major classes of HDAC inhibitors: hydroxamic acids, 2-amino- benzanilides, and cyclic peptides.	Hydroxamic Acids	146-162	histone deacetylase 9	Homo sapiens	129-133
18952609-7	2008	Hydroxamic acid-based metalloproteinase inhibitors block the release of sRAGE, and by RNA interference experiments we identified ADAM10 and MMP9 to be involved in RAGE shedding.	Hydroxamic Acids	0-15	ADAM metallopeptidase domain 10	Homo sapiens	129-135
18952609-7	2008	Hydroxamic acid-based metalloproteinase inhibitors block the release of sRAGE, and by RNA interference experiments we identified ADAM10 and MMP9 to be involved in RAGE shedding.	Hydroxamic Acids	0-15	matrix metallopeptidase 9	Homo sapiens	140-144
18952609-7	2008	Hydroxamic acid-based metalloproteinase inhibitors block the release of sRAGE, and by RNA interference experiments we identified ADAM10 and MMP9 to be involved in RAGE shedding.	Hydroxamic Acids	0-15	advanced glycosylation end-product specific receptor	Homo sapiens	73-77
18838793-0	2008	Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level.	Hydroxamic Acids	0-15	histone deacetylase 9	Homo sapiens	57-76
18701301-1	2008	A series of hydroxamic acids with conjugated structure was designed and synthesized to explore the possible HDAC subtype selectivity by testing these compounds against recombinant human HDAC1 and HDAC4.	Hydroxamic Acids	12-28	histone deacetylase 1	Homo sapiens	186-191
18701301-1	2008	A series of hydroxamic acids with conjugated structure was designed and synthesized to explore the possible HDAC subtype selectivity by testing these compounds against recombinant human HDAC1 and HDAC4.	Hydroxamic Acids	12-28	histone deacetylase 4	Homo sapiens	196-201
18054239-1	2008	We synthesized biarylalanine-containing hydroxamic acids and tested them on immunoprecipitated HDAC1 and HDAC6 and show a subtype selectivity for HDAC6 that was confirmed in cells by Western blot (tubulin vs histones).	Hydroxamic Acids	40-56	histone deacetylase 1	Homo sapiens	95-100
18054239-1	2008	We synthesized biarylalanine-containing hydroxamic acids and tested them on immunoprecipitated HDAC1 and HDAC6 and show a subtype selectivity for HDAC6 that was confirmed in cells by Western blot (tubulin vs histones).	Hydroxamic Acids	40-56	histone deacetylase 6	Homo sapiens	105-110
18054239-1	2008	We synthesized biarylalanine-containing hydroxamic acids and tested them on immunoprecipitated HDAC1 and HDAC6 and show a subtype selectivity for HDAC6 that was confirmed in cells by Western blot (tubulin vs histones).	Hydroxamic Acids	40-56	histone deacetylase 6	Homo sapiens	146-151
17868033-7	2008	The hydroxamic acid-derived compounds (trichostatin A, NVP-LAQ824, panobinostat, ITF2357, vorinostat and belinostat) were potent pan-HDAC inhibitors.	Hydroxamic Acids	4-19	histone deacetylase 9	Homo sapiens	133-137
19090524-1	2009	We synthesized hydroxamic acids with a pyridylalanine substructure and identified them as selective inhibitors of human recombinant HDAC6.	Hydroxamic Acids	15-31	histone deacetylase 6	Homo sapiens	132-137
18673140-0	2008	Allosteric inhibition of [(125I)] ET-1 binding to ET(A) receptors by aldoxime and hydroxamic acid derivatives.	Hydroxamic Acids	82-97	endothelin 1	Rattus norvegicus	34-38
18673140-0	2008	Allosteric inhibition of [(125I)] ET-1 binding to ET(A) receptors by aldoxime and hydroxamic acid derivatives.	Hydroxamic Acids	82-97	endothelin receptor type A	Rattus norvegicus	50-55
16728695-2	2006	LBH589 is a novel hydroxamic acid derivative that at low nanomolar concentrations induces apoptosis in MM cells resistant to conventional therapies via caspase activation and poly-(ADP-ribose) polymerase (PARP) cleavage.	Hydroxamic Acids	18-33	poly(ADP-ribose) polymerase 1	Homo sapiens	175-203
17699868-0	2007	Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.	Hydroxamic Acids	0-15	estrogen receptor 1	Homo sapiens	66-89
17606765-2	2007	We showed that suberoylanilide hydroxamic acid (SAHA; vorinostat), one of the histone deacetylase inhibitors derived from hydroxamic acid, caused a dramatic decrease (90%) in protein levels of cyclin D1 after 8-hour exposure to SAHA (5 muM) in MCL lines (SP49, SP53, Jeko1).	Hydroxamic Acids	31-46	cyclin D1	Homo sapiens	193-202
17699868-2	2007	By inhibiting HDAC6, the hydroxamic acid analogue pan-HDAC inhibitors (HA-HDI; e.g., LAQ824, LBH589, and vorinostat) induce hyperacetylation of the HDAC6 substrates alpha-tubulin and hsp90.	Hydroxamic Acids	25-40	histone deacetylase 6	Homo sapiens	14-19
17699868-2	2007	By inhibiting HDAC6, the hydroxamic acid analogue pan-HDAC inhibitors (HA-HDI; e.g., LAQ824, LBH589, and vorinostat) induce hyperacetylation of the HDAC6 substrates alpha-tubulin and hsp90.	Hydroxamic Acids	25-40	histone deacetylase 6	Homo sapiens	148-153
17699868-2	2007	By inhibiting HDAC6, the hydroxamic acid analogue pan-HDAC inhibitors (HA-HDI; e.g., LAQ824, LBH589, and vorinostat) induce hyperacetylation of the HDAC6 substrates alpha-tubulin and hsp90.	Hydroxamic Acids	25-40	heat shock protein 90 alpha family class A member 1	Homo sapiens	183-188
17419603-2	2007	An HDAC inhibitor based on a cyclic peptide mimic of known structure, linked by an aliphatic chain to a hydroxamic acid, was designed and synthesized.	Hydroxamic Acids	104-119	histone deacetylase 9	Homo sapiens	3-7
17318264-2	2007	We sought to establish whether the potent and specific hydroxamic acid class of histone deacetylase (HDAC) inhibitors activates SMN2 gene expression in vivo and modulates the SMA disease phenotype when delivered after disease onset.	Hydroxamic Acids	55-70	glutamate receptor, metabotropic 7	Mus musculus	128-132
17318264-7	2007	These results indicate that the hydroxamic acid class of HDAC inhibitors activates SMN2 gene expression in vivo and has an ameliorating effect on the SMA disease phenotype when administered after disease onset.	Hydroxamic Acids	32-47	glutamate receptor, metabotropic 7	Mus musculus	83-87
16997560-2	2006	The union of the hydroxamic acid zinc-chelator with a urea isostere for the glu-cys amide bond led to a glutathione analog which retained inhibitory potency toward glyoxalase-I while possessing resistance toward gamma-glutamyltranspeptidase mediated breakdown.	Hydroxamic Acids	17-32	glyoxalase I	Homo sapiens	164-176
16728695-2	2006	LBH589 is a novel hydroxamic acid derivative that at low nanomolar concentrations induces apoptosis in MM cells resistant to conventional therapies via caspase activation and poly-(ADP-ribose) polymerase (PARP) cleavage.	Hydroxamic Acids	18-33	poly(ADP-ribose) polymerase 1	Homo sapiens	205-209
16603129-1	2006	Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453 have been solved at 2.01 and 2.37A resolutions, respectively.	Hydroxamic Acids	108-123	matrix metallopeptidase 3	Homo sapiens	52-65
16951198-9	2006	Hydroxamic acid derivatives with known activity against both class I and class II HDACs were effective in inhibiting HIF-1 alpha at low nanomolar concentrations.	Hydroxamic Acids	0-15	hypoxia inducible factor 1 subunit alpha	Homo sapiens	117-128
16723227-1	2006	delta-Lactam-based hydroxamic acids, inhibitors of histone deacetylase (HDAC), have been synthesized via ring closure metathesis of key diene intermediates followed by conversion to hydroxamic acid analogues.	Hydroxamic Acids	19-34	histone deacetylase 9	Homo sapiens	51-70
16723227-1	2006	delta-Lactam-based hydroxamic acids, inhibitors of histone deacetylase (HDAC), have been synthesized via ring closure metathesis of key diene intermediates followed by conversion to hydroxamic acid analogues.	Hydroxamic Acids	19-34	histone deacetylase 9	Homo sapiens	72-76
16723227-2	2006	The hydroxamic acids 12a, 12b, and 17c showed potent inhibitory activity in HDAC enzyme assay.	Hydroxamic Acids	4-20	histone deacetylase 9	Homo sapiens	76-80
16603129-0	2006	Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.	Hydroxamic Acids	108-123	matrix metallopeptidase 3	Homo sapiens	52-65
16603129-0	2006	Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.	Hydroxamic Acids	108-123	matrix metallopeptidase 3	Homo sapiens	67-72
16603129-0	2006	Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453.	Hydroxamic Acids	108-123	matrix metallopeptidase 13	Homo sapiens	78-99
16603129-1	2006	Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453 have been solved at 2.01 and 2.37A resolutions, respectively.	Hydroxamic Acids	108-123	matrix metallopeptidase 3	Homo sapiens	67-72
16603129-1	2006	Crystal structures of the catalytic domain of human stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) with a hydroxamic acid inhibitor SM-25453 have been solved at 2.01 and 2.37A resolutions, respectively.	Hydroxamic Acids	108-123	matrix metallopeptidase 13	Homo sapiens	78-99
16948471-3	2006	Simple stable molecules containing the hydroxamic acid functionality have been shown to inhibit 5-lipoxygenase.	Hydroxamic Acids	39-54	linoleate 9S-lipoxygenase-4	Glycine max	98-110
16585977-0	2006	Models of hypoxia activated prodrugs: Co(III) complexes of hydroxamic acids.	Hydroxamic Acids	59-75	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	38-45
16585977-1	2006	Co(III) complexes of simple hydroxamic acids have been evaluated as models of hypoxia activated prodrugs containing MMP inhibitors.	Hydroxamic Acids	28-44	mitochondrially encoded cytochrome c oxidase III	Homo sapiens	0-7
15601584-3	2004	Recently, the solution structure of the catalytic domain of MMP-2 complexed with a hydroxamic acid inhibitor (SC-74020) was published by Feng et al.	Hydroxamic Acids	83-98	matrix metallopeptidase 2	Homo sapiens	60-65
15716589-2	2005	It is conceivable, therefore, to hypothesize that the cytostatic effect induced by this agent is at least partially associated with a molecular mechanism that involves histone deacetylase 1 (HDAC1) inhibition, as demonstrated for sodium butyrate and other specific inhibitors, such as trichostatin A and hydroxamic acids.	Hydroxamic Acids	304-320	histone deacetylase 1	Homo sapiens	168-189
15716589-2	2005	It is conceivable, therefore, to hypothesize that the cytostatic effect induced by this agent is at least partially associated with a molecular mechanism that involves histone deacetylase 1 (HDAC1) inhibition, as demonstrated for sodium butyrate and other specific inhibitors, such as trichostatin A and hydroxamic acids.	Hydroxamic Acids	304-320	histone deacetylase 1	Homo sapiens	191-196
15908214-1	2005	New inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) were discovered with a pyrimidine-2,4,6-trione in place of the commonly used hydroxamic acid.	Hydroxamic Acids	148-163	ADAM metallopeptidase domain 17	Homo sapiens	18-63
15908214-1	2005	New inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) were discovered with a pyrimidine-2,4,6-trione in place of the commonly used hydroxamic acid.	Hydroxamic Acids	148-163	ADAM metallopeptidase domain 17	Homo sapiens	65-69
15799868-7	2005	In vitro zymography and enzyme assays showed for both hydroxamic acid and carboxylic acid compounds a good inhibition activity and a high selectivity for MMP-2.	Hydroxamic Acids	54-69	matrix metallopeptidase 2	Mus musculus	154-159
15582436-0	2005	N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.	Hydroxamic Acids	58-73	alanyl aminopeptidase, membrane	Bos taurus	93-109
15498654-3	2004	We replaced the epoxyketone moiety of chlamydocin with hydroxamic acid to design potent and reversible inhibitors of HDAC.	Hydroxamic Acids	55-70	histone deacetylase 9	Homo sapiens	117-121
15937340-1	2005	The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce acetylation and inhibit the ATP binding and chaperone function of heat shock protein (HSP) 90.	Hydroxamic Acids	4-19	heat shock protein 90 alpha family class A member 1	Homo sapiens	194-221
15937340-1	2005	The hydroxamic acid (HAA) analogue pan-histone deacetylase (HDAC) inhibitors (HDIs) LAQ824 and LBH589 have been shown to induce acetylation and inhibit the ATP binding and chaperone function of heat shock protein (HSP) 90.	Hydroxamic Acids	21-24	heat shock protein 90 alpha family class A member 1	Homo sapiens	194-221
15297431-1	2004	We have developed previously a class of synthetic hybrid histone deacetylase (HDAC) inhibitors, which were built from hydroxamic acid of trichostatin A and pyridyl ring of MS-275.	Hydroxamic Acids	118-133	histone deacetylase 9	Homo sapiens	57-76
15297431-1	2004	We have developed previously a class of synthetic hybrid histone deacetylase (HDAC) inhibitors, which were built from hydroxamic acid of trichostatin A and pyridyl ring of MS-275.	Hydroxamic Acids	118-133	histone deacetylase 9	Homo sapiens	78-82
14741217-3	2004	We have solved the structure of the catalytic domain (cd) of MT3-MMP/MMP-16 in complex with the hydroxamic acid inhibitor batimastat.	Hydroxamic Acids	96-111	matrix metallopeptidase 16	Homo sapiens	61-68
15161353-3	2004	In the present study, we observed that several potent HDAC inhibitors, including trichostatin A, suberoylanilide hydroxamic acid, M344 (an analogue of hydroxamic acid), and the cyclic tetrapeptide, depsipeptide (FR90228), modulate cellular responses to ionizing radiation in cells of two human squamous carcinoma lines (SQ-20B and SCC-35), previously characterized as intrinsically resistant to radiation.	Hydroxamic Acids	113-128	histone deacetylase 9	Homo sapiens	54-58
15122596-3	2004	Oxamflatin (Ox), a novel hydroxamic acid derivative, inhibits u-PA mRNA expression and proteolytic activity while simultaneously upregulating the expression of the natural inhibitor of u-PA, plasminogen activator inhibitor type 2 (PAI-2) in metastatic cancer cells.	Hydroxamic Acids	25-40	plasminogen activator, urokinase	Homo sapiens	62-66
14741217-3	2004	We have solved the structure of the catalytic domain (cd) of MT3-MMP/MMP-16 in complex with the hydroxamic acid inhibitor batimastat.	Hydroxamic Acids	96-111	matrix metallopeptidase 16	Homo sapiens	69-75
12770822-4	2003	Hydroxamic acid-based HDAC inhibitors like TSA and suberoylanilide hydroxamic acid (SAHA) promote acetylation of cytoplasmic alpha-tubulin as well as histones, a modification also suppressed by ITSAs.	Hydroxamic Acids	0-15	histone deacetylase 9	Homo sapiens	22-26
14709625-3	2004	Raloxifene has also been shown to be a noncompetitive inhibitor of an aldehyde oxidase-catalyzed reduction reaction of a hydroxamic acid-containing compound, with a K(i) of 51 nM.	Hydroxamic Acids	121-136	aldehyde oxidase 1	Homo sapiens	70-86
14518968-0	2003	Inhibitory activities of semicarbazide-sensitive amine oxidase and angiotensin converting enzyme of pectin hydroxamic acid.	Hydroxamic Acids	107-122	amine oxidase copper containing 2	Homo sapiens	25-62
14578462-2	2003	Present studies demonstrate that exposure to a novel hydroxamic acid analogue histone deacetylase inhibitor, LAQ824, induced p21WAF1 and p27KIP1 and caused growth arrest and apoptosis of human breast cancer SKBR-3 and BT-474 cells that possess amplification and overexpression of Her-2/neu.	Hydroxamic Acids	53-68	cyclin dependent kinase inhibitor 1B	Homo sapiens	137-144
14578462-2	2003	Present studies demonstrate that exposure to a novel hydroxamic acid analogue histone deacetylase inhibitor, LAQ824, induced p21WAF1 and p27KIP1 and caused growth arrest and apoptosis of human breast cancer SKBR-3 and BT-474 cells that possess amplification and overexpression of Her-2/neu.	Hydroxamic Acids	53-68	erb-b2 receptor tyrosine kinase 2	Homo sapiens	280-289
14579524-3	2003	Significant advances have been reported in the design and synthesis of potent and selective inhibitors of MMP-13 using hydroxamic acid and non-hydroxamate zinc chelators on a variety of scaffolds.	Hydroxamic Acids	119-134	matrix metallopeptidase 13	Homo sapiens	106-112
12777399-7	2003	The ADAM8-dependent release of sCD23 and the endogenous release from B cell lines could be similarly inhibited by a hydroxamic acid, metalloprotease inhibitor compound.	Hydroxamic Acids	116-131	ADAM metallopeptidase domain 8	Homo sapiens	4-9
12748171-2	2003	Because hydroxamic acid-based metalloprotease inhibitors prevent shedding of both TNFR1 and the interleukin-6 receptor (IL-6Ralpha), we hypothesized that ARTS-1 might also regulate shedding of IL-6Ralpha, a member of the type I cytokine receptor superfamily that is structurally different from TNFR1.	Hydroxamic Acids	8-23	TNF receptor superfamily member 1A	Homo sapiens	82-87
12748171-2	2003	Because hydroxamic acid-based metalloprotease inhibitors prevent shedding of both TNFR1 and the interleukin-6 receptor (IL-6Ralpha), we hypothesized that ARTS-1 might also regulate shedding of IL-6Ralpha, a member of the type I cytokine receptor superfamily that is structurally different from TNFR1.	Hydroxamic Acids	8-23	interleukin 6 receptor	Homo sapiens	96-118
12748171-2	2003	Because hydroxamic acid-based metalloprotease inhibitors prevent shedding of both TNFR1 and the interleukin-6 receptor (IL-6Ralpha), we hypothesized that ARTS-1 might also regulate shedding of IL-6Ralpha, a member of the type I cytokine receptor superfamily that is structurally different from TNFR1.	Hydroxamic Acids	8-23	interleukin 6 receptor	Homo sapiens	120-130
12748171-2	2003	Because hydroxamic acid-based metalloprotease inhibitors prevent shedding of both TNFR1 and the interleukin-6 receptor (IL-6Ralpha), we hypothesized that ARTS-1 might also regulate shedding of IL-6Ralpha, a member of the type I cytokine receptor superfamily that is structurally different from TNFR1.	Hydroxamic Acids	8-23	endoplasmic reticulum aminopeptidase 1	Homo sapiens	154-160
12913293-6	2003	A five-carbon chain and hydroxamic acid, essential for histone deacetylase inhibition, were indispensable for this effect, and trichostatin A stimulated glucose uptake as well.	Hydroxamic Acids	24-39	histone deacetylase 9	Homo sapiens	55-74
12798312-1	2003	A series of hydroxamic acids has been prepared as potential inhibitors of glutamate carboxypeptidase II (GCP II).	Hydroxamic Acids	12-28	folate hydrolase 1	Homo sapiens	74-103
12798312-1	2003	A series of hydroxamic acids has been prepared as potential inhibitors of glutamate carboxypeptidase II (GCP II).	Hydroxamic Acids	12-28	folate hydrolase 1	Homo sapiens	105-111
12207002-4	2002	In addition, we have determined the structures of LTA4 hydrolase in complex with two selective tight-binding inhibitors, a thioamine and a hydroxamic acid.	Hydroxamic Acids	139-154	leukotriene A4 hydrolase	Homo sapiens	50-64
12456388-7	2003	Our results show that 1) cyclic stretch led to increased release and activation of MMP-2 and MMP-1; 2) the activation of MMP-2 was accompanied by an increase in membrane type-1 MMP (MT1-MMP) and inhibited by a hydroxamic acid-derived inhibitor of MMPs (Prinomastat, AG3340); and 3) the MMP-2 release and activation were preceded by an increase in production of extracellular MMP inducer (EMMPRIN).	Hydroxamic Acids	210-225	matrix metallopeptidase 2	Homo sapiens	121-126
12456388-7	2003	Our results show that 1) cyclic stretch led to increased release and activation of MMP-2 and MMP-1; 2) the activation of MMP-2 was accompanied by an increase in membrane type-1 MMP (MT1-MMP) and inhibited by a hydroxamic acid-derived inhibitor of MMPs (Prinomastat, AG3340); and 3) the MMP-2 release and activation were preceded by an increase in production of extracellular MMP inducer (EMMPRIN).	Hydroxamic Acids	210-225	matrix metallopeptidase 2	Homo sapiens	121-126
12644016-11	2003	CONCLUCION: Our data indicate that hydroxamic acid-based HDAC inhibitors are potent gamma-globin gene inducers and that the concentration range of their effects on gamma gene expression can be correlated roughly with their HDAC inhibitory potencies.	Hydroxamic Acids	35-50	histone deacetylase 9	Homo sapiens	57-61
12644016-11	2003	CONCLUCION: Our data indicate that hydroxamic acid-based HDAC inhibitors are potent gamma-globin gene inducers and that the concentration range of their effects on gamma gene expression can be correlated roughly with their HDAC inhibitory potencies.	Hydroxamic Acids	35-50	histone deacetylase 9	Homo sapiens	223-227
12517439-4	2003	The structural modification of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids enabled us to establish the following structure-activity relationships; the existence of the hydroxamic acid, the sulfonamide, and the phenyl moieties are crucial for a potent HB-EGF shedding inhibitory activity, and the stereochemistry of the alpha carbon of hydroxamic acid is also important.	Hydroxamic Acids	77-92	heparin binding EGF like growth factor	Homo sapiens	270-276
12147339-0	2002	Solution structure and backbone dynamics of the catalytic domain of matrix metalloproteinase-2 complexed with a hydroxamic acid inhibitor.	Hydroxamic Acids	112-127	matrix metallopeptidase 2	Homo sapiens	68-94
12147339-2	2002	Here, we describe the solution structure of a catalytic domain of MMP-2 complexed with a hydroxamic acid inhibitor (SC-74020), determined by three-dimensional heteronuclear NMR spectroscopy.	Hydroxamic Acids	89-104	matrix metallopeptidase 2	Homo sapiens	66-71
12678732-4	2002	In the class of HDAC inhibitors, now included a short-chain fatty acids, such as 4-phenylbutyrate and valporic acid, hydroxamic acids, such as suberoylanilide hydroxamic acid (SAHA), pyroxamide, trichostatin A, oxamflatin and CHAPSs, cyclic tetrapeptides, such as trapoxin, apicidin and depsipeptide-also known as FK-228 or FR 901228, and benzamides, such as MS-275.	Hydroxamic Acids	117-133	histone deacetylase 9	Homo sapiens	16-20
11592410-2	2001	Different classes of MMP inhibitors, including hydroxamic acids, phosphinic acids and thiols, have been previously described.	Hydroxamic Acids	47-63	matrix metallopeptidase 2	Homo sapiens	21-24
11677124-0	2001	Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.	Hydroxamic Acids	23-38	ADAM metallopeptidase domain 17	Homo sapiens	53-98
11585440-0	2001	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1", a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Hydroxamic Acids	25-41	tumor necrosis factor	Homo sapiens	110-119
11585440-0	2001	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1", a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Hydroxamic Acids	25-41	tumor necrosis factor	Homo sapiens	200-209
11585440-1	2001	SAR exploration at P1" using an anti-succinate-based macrocyclic hydroxamic acid as a template led to the identification of several bulky biphenylmethyl P1" derivatives which confer potent porcine TACE and anti-TNF-alpha cellular activities with high selectivity versus most of the MMPs screened.	Hydroxamic Acids	65-80	ADAM metallopeptidase domain 17	Homo sapiens	197-201
11585440-1	2001	SAR exploration at P1" using an anti-succinate-based macrocyclic hydroxamic acid as a template led to the identification of several bulky biphenylmethyl P1" derivatives which confer potent porcine TACE and anti-TNF-alpha cellular activities with high selectivity versus most of the MMPs screened.	Hydroxamic Acids	65-80	tumor necrosis factor	Homo sapiens	211-220
11575929-4	2001	We describe here the crystal structure of the catalytic domain of MMP-12 in complex with a hydroxamic acid inhibitor, CGS27023A.	Hydroxamic Acids	91-106	matrix metallopeptidase 12	Homo sapiens	66-72
11472217-1	2001	To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the P1 and P2" residues of acyclic anti-succinate-based hydroxamic acids.	Hydroxamic Acids	130-146	tumor necrosis factor	Mus musculus	14-23
11472217-1	2001	To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the P1 and P2" residues of acyclic anti-succinate-based hydroxamic acids.	Hydroxamic Acids	130-146	tumor necrosis factor	Mus musculus	25-52
11472217-1	2001	To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the P1 and P2" residues of acyclic anti-succinate-based hydroxamic acids.	Hydroxamic Acids	130-146	a disintegrin and metallopeptidase domain 17	Mus musculus	73-77
11472217-1	2001	To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the P1 and P2" residues of acyclic anti-succinate-based hydroxamic acids.	Hydroxamic Acids	130-146	zinc finger protein 185	Mus musculus	162-171
11472217-1	2001	To search for TNF-alpha (tumor necrosis factor alpha) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the P1 and P2" residues of acyclic anti-succinate-based hydroxamic acids.	Hydroxamic Acids	214-230	a disintegrin and metallopeptidase domain 17	Mus musculus	73-77
10948197-3	2000	FGF-2-stimulated migration was inhibited by a hydroxamic acid inhibitor of matrix metalloproteinases and by a neutralizing anti-collagenase-1 antibody.	Hydroxamic Acids	46-61	fibroblast growth factor 2	Homo sapiens	0-5
11497466-7	2001	Double mutants of rhm1 and bx1, a hydroxamic acid-deficient mutant, indicate that rhm1 resistance is hydroxamic acid independent.	Hydroxamic Acids	34-49	RHM1	Zea mays	82-86
11497466-7	2001	Double mutants of rhm1 and bx1, a hydroxamic acid-deficient mutant, indicate that rhm1 resistance is hydroxamic acid independent.	Hydroxamic Acids	101-116	RHM1	Zea mays	82-86
11382149-1	2001	With the aim of developing new inhibitors of 17 alpha-hydroxylase/C17,20-lyase (P450 17, CYP 17), two steroidal hydroxamic acids (compounds 2 and 3) were synthesized and evaluated as inhibitors of CYP 17.	Hydroxamic Acids	112-128	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	89-95
10925303-6	2000	A hydroxamic acid compound (KB8301) almost completely inhibited shedding of TNF-R55 and to a lesser degree shedding of TNF-R75.	Hydroxamic Acids	2-17	TNF receptor superfamily member 1A	Homo sapiens	76-83
10986126-0	2000	High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.	Hydroxamic Acids	110-125	matrix metallopeptidase 13	Homo sapiens	70-83
10986126-0	2000	High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.	Hydroxamic Acids	110-125	matrix metallopeptidase 13	Homo sapiens	85-91
10986126-1	2000	The high-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a sulfonamide derivative of a hydroxamic acid compound (WAY-151693) has been determined by multidimensional heteronuclear NMR.	Hydroxamic Acids	142-157	matrix metallopeptidase 13	Homo sapiens	74-87
10986126-1	2000	The high-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a sulfonamide derivative of a hydroxamic acid compound (WAY-151693) has been determined by multidimensional heteronuclear NMR.	Hydroxamic Acids	142-157	matrix metallopeptidase 13	Homo sapiens	89-95
10925303-6	2000	A hydroxamic acid compound (KB8301) almost completely inhibited shedding of TNF-R55 and to a lesser degree shedding of TNF-R75.	Hydroxamic Acids	2-17	TNF receptor superfamily member 1B	Homo sapiens	119-126
10753951-8	2000	These different processes were inhibited by hydroxamic acid-based synthetic MMP inhibitors and rTIMP-2, but not by rTIMP-1 or cysteine, serine, or aspartic proteinase inhibitors.	Hydroxamic Acids	44-59	matrix metallopeptidase 2	Homo sapiens	76-79
11004477-6	2000	We have identified the hydroxamic acid derivative oxamflatin, previously noted to revert the malignant phenotype in K-ras-transformed NIH-3T3 cells, as capable of upregulating PAI-2 and simultaneously suppressing u-PA expression in two different cell systems.	Hydroxamic Acids	23-38	serine (or cysteine) peptidase inhibitor, clade B, member 2	Mus musculus	176-181
11004477-6	2000	We have identified the hydroxamic acid derivative oxamflatin, previously noted to revert the malignant phenotype in K-ras-transformed NIH-3T3 cells, as capable of upregulating PAI-2 and simultaneously suppressing u-PA expression in two different cell systems.	Hydroxamic Acids	23-38	plasminogen activator, urokinase	Mus musculus	213-217
10506112-9	1999	UGT1A1 demonstrated more extensive metabolism of the hydroxamic acid, N-hydroxy-N,N"-diacetylbenzidine, and the ring oxidation product, 3-OH-N,N"-diacetylbenzidine, than it did for the other six amines.	Hydroxamic Acids	53-68	UDP glucuronosyltransferase family 1 member A1	Homo sapiens	0-6
10614784-5	1999	A specific hydroxamic acid-based inhibitor of processing, BB1101 (British Biotech), was found to increase the total cellular levels of whole-cell, 26-kDa, precursor TNF-alpha by 2.2-fold.	Hydroxamic Acids	11-26	tumor necrosis factor	Homo sapiens	165-174
10579851-2	1999	Current inhibitors of TACE such as succinate-based hydroxamic acids exemplified by Marimastat (TACE IC(50): 3.8 nM; blood IC(50): 7 microM) and BB1101 (TACE IC(50): 0.2 nM; blood IC(50): 2.3 microM) suffer from modest potency in blood and poor in vivo properties.	Hydroxamic Acids	51-67	ADAM metallopeptidase domain 17	Homo sapiens	22-26
10579851-2	1999	Current inhibitors of TACE such as succinate-based hydroxamic acids exemplified by Marimastat (TACE IC(50): 3.8 nM; blood IC(50): 7 microM) and BB1101 (TACE IC(50): 0.2 nM; blood IC(50): 2.3 microM) suffer from modest potency in blood and poor in vivo properties.	Hydroxamic Acids	51-67	ADAM metallopeptidase domain 17	Homo sapiens	95-99
10579851-2	1999	Current inhibitors of TACE such as succinate-based hydroxamic acids exemplified by Marimastat (TACE IC(50): 3.8 nM; blood IC(50): 7 microM) and BB1101 (TACE IC(50): 0.2 nM; blood IC(50): 2.3 microM) suffer from modest potency in blood and poor in vivo properties.	Hydroxamic Acids	51-67	ADAM metallopeptidase domain 17	Homo sapiens	95-99
10521266-0	1999	Analysis of the binding of hydroxamic acid and carboxylic acid inhibitors to the stromelysin-1 (matrix metalloproteinase-3) catalytic domain by isothermal titration calorimetry.	Hydroxamic Acids	27-42	matrix metallopeptidase 3	Homo sapiens	81-94
10068670-9	1999	Moreover, the hydroxamic acid derivative BB-24 demonstrated dose-dependent inhibition of cytokine-, PMA-, and VEGF-stimulated shedding, suggesting that the tie-1 protease was a metalloprotease.	Hydroxamic Acids	14-29	vascular endothelial growth factor A	Homo sapiens	110-114
10353819-1	1999	The solution structure of the catalytic fragment of human fibroblast collagenase (MMP-1) complexed with a sulfonamide derivative of a hydroxamic acid compound (CGS-27023A) has been determined using two-dimensional and three-dimensional heteronuclear NMR spectroscopy.	Hydroxamic Acids	134-149	matrix metallopeptidase 1	Homo sapiens	82-87
10068670-9	1999	Moreover, the hydroxamic acid derivative BB-24 demonstrated dose-dependent inhibition of cytokine-, PMA-, and VEGF-stimulated shedding, suggesting that the tie-1 protease was a metalloprotease.	Hydroxamic Acids	14-29	tyrosine kinase with immunoglobulin like and EGF like domains 1	Homo sapiens	156-161
9888835-1	1999	A new series of hydroxamic acid-based matrix metalloproteinase (MMP) inhibitors containing a unique phosphinamide motif derived from D-amino acid was designed, synthesized, and tested for enzyme inhibition.	Hydroxamic Acids	16-31	matrix metallopeptidase 1	Homo sapiens	64-67
9658575-1	1998	I. Synthesis and 5-lipoxygenase-inhibitory activity of novel hydroxamic acid derivatives.	Hydroxamic Acids	61-76	arachidonate 5-lipoxygenase	Rattus norvegicus	17-31
9684866-4	1998	In addition, there was a different effect of three hydroxamic acid-based inhibitors (batimastat, compound 1 and compound 4) towards TNF-alpha convertase as compared to ACE secretase and alpha-secretase.	Hydroxamic Acids	51-66	ADAM metallopeptidase domain 17	Homo sapiens	132-152
9484239-3	1998	The release of the amyloid precursor protein from both SH-SY5Y and IMR-32 neuronal cells by alpha-secretase was blocked by batimastat and other related synthetic hydroxamic acid-based zinc metalloprotease inhibitors, but not by the structurally unrelated zinc metalloprotease inhibitors enalaprilat and phosphoramidon.	Hydroxamic Acids	162-177	amyloid beta precursor protein	Homo sapiens	19-44
9871623-1	1998	A series of hydroxamic acids related to the non-selective matrix metalloproteinase inhibitor Batimastat has been prepared, some members of which are potent inhibitors of the processing of the low affinity IgE receptor (CD 23).	Hydroxamic Acids	12-28	Fc epsilon receptor II	Homo sapiens	219-224
9464356-0	1998	Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.	Hydroxamic Acids	19-34	phosphodiesterase 4A	Homo sapiens	55-79
9464356-0	1998	Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.	Hydroxamic Acids	19-34	phosphodiesterase 4A	Homo sapiens	81-85
9464356-0	1998	Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.	Hydroxamic Acids	19-34	phosphodiesterase 4A	Homo sapiens	202-206
7500022-4	1995	Treatment with hydroxamic acid inhibitors of matrix metalloproteinases specifically led to accumulation of membrane-type FasL (p40) on the surface of human FasL cDNA transfectants and activated human T cells, as estimated by surface immunofluorescence and immunoprecipitation with newly established anti-human FasL monoclonal antibodies.	Hydroxamic Acids	15-30	Fas ligand	Homo sapiens	121-125
9305723-4	1997	Using hydroxamic acid-based inhibitors of this class of proteases (BB-3103, Ro31-9790), we have observed a clear inhibitory effect on Fc gammaRIIIb shedding after PMA stimulation of neutrophils or induction of apoptosis.	Hydroxamic Acids	6-21	Fc gamma receptor IIIb	Homo sapiens	134-147
9398185-6	1997	The resonance at 14.9 ppm is absent and the resonance at 10.9 ppm is much weaker in the TIM complex of PGA, which lacks the hydroxamic acid (-NHOH) moiety.	Hydroxamic Acids	124-139	triosephosphate isomerase 1	Homo sapiens	88-91
9406876-2	1997	The synthetic hydroxamic acid based metalloprotease inhibitor TAPI blocks cleavage of cell surface TNF and thus reduces levels of the mature 17-kDa TNF polypeptide in activated macrophages and T-cells.	Hydroxamic Acids	14-29	tumor necrosis factor	Mus musculus	99-102
9406876-2	1997	The synthetic hydroxamic acid based metalloprotease inhibitor TAPI blocks cleavage of cell surface TNF and thus reduces levels of the mature 17-kDa TNF polypeptide in activated macrophages and T-cells.	Hydroxamic Acids	14-29	tumor necrosis factor	Mus musculus	148-151
9071708-1	1997	The synthetic inhibitor of matrix metalloproteinases (MMP) Ro 31-9790, a hydroxamic-acid derivative, was investigated for its effect on rat mesangial cells (MC) in culture.	Hydroxamic Acids	73-88	matrix metallopeptidase 2	Rattus norvegicus	54-57
8662605-4	1996	The hydroxamic acid-based inhibitor of zinc-dependent matrix metalloproteinases Ro 31-9790 completely prevented shedding of cell surface L-selectin from leucocytes in mouse, rat, and man.	Hydroxamic Acids	4-19	selectin, lymphocyte	Mus musculus	137-147
7500022-4	1995	Treatment with hydroxamic acid inhibitors of matrix metalloproteinases specifically led to accumulation of membrane-type FasL (p40) on the surface of human FasL cDNA transfectants and activated human T cells, as estimated by surface immunofluorescence and immunoprecipitation with newly established anti-human FasL monoclonal antibodies.	Hydroxamic Acids	15-30	interleukin 9	Homo sapiens	127-130
7500022-4	1995	Treatment with hydroxamic acid inhibitors of matrix metalloproteinases specifically led to accumulation of membrane-type FasL (p40) on the surface of human FasL cDNA transfectants and activated human T cells, as estimated by surface immunofluorescence and immunoprecipitation with newly established anti-human FasL monoclonal antibodies.	Hydroxamic Acids	15-30	Fas ligand	Homo sapiens	156-160
7500022-4	1995	Treatment with hydroxamic acid inhibitors of matrix metalloproteinases specifically led to accumulation of membrane-type FasL (p40) on the surface of human FasL cDNA transfectants and activated human T cells, as estimated by surface immunofluorescence and immunoprecipitation with newly established anti-human FasL monoclonal antibodies.	Hydroxamic Acids	15-30	Fas ligand	Homo sapiens	156-160
7783143-1	1995	Hydroxamic acids 6a-h, derived from malonyl amino acids, and 25a-d, derived from succinyl amino acids, were synthesized as inhibitors of human bronchiolar smooth muscle endothelin-converting enzyme (HBSM ECE).	Hydroxamic Acids	0-16	endothelin converting enzyme 1	Homo sapiens	204-207
7696992-0	1994	Reductase activity of aldehyde oxidase toward the carcinogen N-hydroxy-2-acetylaminofluorene and the related hydroxamic acids.	Hydroxamic Acids	109-125	aldehyde oxidase 1	Homo sapiens	22-38
1322694-0	1992	Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids.	Hydroxamic Acids	109-125	matrix metallopeptidase 1	Homo sapiens	25-47
7889863-5	1994	Studies also concern oxidations of the hydroxamic acids by rat peritoneal neutrophils stimulated to undergo respiratory burst and release myeloperoxidase in medium-containing 0.14 M Cl- +/- 0.1 mM Br-.	Hydroxamic Acids	39-55	myeloperoxidase	Rattus norvegicus	138-153
24242719-1	1994	Phloem sap of wheat seedlings differing in whole leaf hydroxamic acid (Hx) concentrations was collected by cutting stylets of feeding aphids.	Hydroxamic Acids	71-73	thiosulfate sulfurtransferase 16, chloroplastic	Triticum aestivum	7-10
1423828-7	1992	Purified aryl sulfotransferase IV (AST IV) converted all hydroxamic acids; N-OH-2AAMPP was a poor substrate.	Hydroxamic Acids	57-73	sulfotransferase family 1A member 1	Rattus norvegicus	9-33
1423828-7	1992	Purified aryl sulfotransferase IV (AST IV) converted all hydroxamic acids; N-OH-2AAMPP was a poor substrate.	Hydroxamic Acids	57-73	sulfotransferase family 1A member 1	Rattus norvegicus	35-41
1322694-1	1992	The hydroxamic acid HONHCOCH2CH(i-Bu)CO-L-Trp-NHMe, isomer 6A (GM 6001), inhibits human skin fibroblast collagenase with Ki of 0.4 nM using the synthetic thiol ester substrate Ac-Pro-Leu-Gly-SCH(i-Bu)CO-Leu-Gly-OEt at pH 6.5.	Hydroxamic Acids	4-19	matrix metallopeptidase 1	Homo sapiens	93-115
1793063-0	1991	Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma.	Hydroxamic Acids	0-16	arachidonate 5-lipoxygenase	Homo sapiens	54-68
1847758-0	1991	Inhibition of 5-lipoxygenase: development of hydroxamic acids and hydroxyureas as potential therapeutic agents.	Hydroxamic Acids	45-61	arachidonate 5-lipoxygenase	Homo sapiens	14-28
34954595-1	2022	In view of histone deacetylases (HDACs) as a promising target for cancer therapy, a series of phthalazino(1,2-b)-quinazolinone units were hybrided with ortho-aminoanilide or hydroxamic acid to serve as multi-target HDAC inhibitors for the treatment of solid tumors.	Hydroxamic Acids	174-189	histone deacetylase 9	Homo sapiens	215-219
2308149-0	1990	Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.	Hydroxamic Acids	0-15	arachidonate 5-lipoxygenase	Homo sapiens	30-44
34847495-4	2022	In the present work, we designed and synthesized a series of quinazoline-based hydroxamic acid derivatives as dual GLP and HDAC inhibitors.	Hydroxamic Acids	79-94	euchromatic histone methyltransferase 1	Mus musculus	115-118
34638665-3	2021	Over the last decades, a diverse range of MMP-2/9 inhibitors has been identified starting from the early hydroxamic acid-based peptidomimetics to the next generation non-hydroxamates.	Hydroxamic Acids	105-120	matrix metallopeptidase 2	Homo sapiens	42-49
34187263-1	2021	A series of thieno(2,3-d)pyrimidine-based hydroxamic acid hybrids was designed and synthesised as multitarget anti-cancer agents, through incorporating the pharmacophore of EGFR, VEGFR2 into the inhibitory functionality of HDAC6.	Hydroxamic Acids	42-57	epidermal growth factor receptor	Homo sapiens	173-177
34187263-1	2021	A series of thieno(2,3-d)pyrimidine-based hydroxamic acid hybrids was designed and synthesised as multitarget anti-cancer agents, through incorporating the pharmacophore of EGFR, VEGFR2 into the inhibitory functionality of HDAC6.	Hydroxamic Acids	42-57	kinase insert domain receptor	Homo sapiens	179-185
34187263-1	2021	A series of thieno(2,3-d)pyrimidine-based hydroxamic acid hybrids was designed and synthesised as multitarget anti-cancer agents, through incorporating the pharmacophore of EGFR, VEGFR2 into the inhibitory functionality of HDAC6.	Hydroxamic Acids	42-57	histone deacetylase 6	Homo sapiens	223-228
34885822-3	2021	In this study, a series of novel CRBN-recruiting HDAC PROTACs were designed and synthesized by linking hydroxamic acid and benzamide with lenalidomide, pomalidomide, and CC-220 through linkers of different lengths and types.	Hydroxamic Acids	103-118	cereblon	Homo sapiens	33-37
34885822-3	2021	In this study, a series of novel CRBN-recruiting HDAC PROTACs were designed and synthesized by linking hydroxamic acid and benzamide with lenalidomide, pomalidomide, and CC-220 through linkers of different lengths and types.	Hydroxamic Acids	103-118	histone deacetylase 9	Homo sapiens	49-53
34634618-4	2021	A docking study revealed that the polar hydroxamic acid retains the interaction with HDAC through a zinc ion and also interacts with some residues of the active site of VEGFR-2.	Hydroxamic Acids	40-55	histone deacetylase 9	Homo sapiens	85-89
34634618-4	2021	A docking study revealed that the polar hydroxamic acid retains the interaction with HDAC through a zinc ion and also interacts with some residues of the active site of VEGFR-2.	Hydroxamic Acids	40-55	kinase insert domain receptor	Homo sapiens	169-176
34517222-3	2021	As a hydrochloride salt, the phenothiazine-based hydroxamic acid W5 with a pyridyl-containing linker motif was identified as a high potent and selective HDAC6 inhibitor.	Hydroxamic Acids	49-64	histone deacetylase 6	Homo sapiens	153-158
34832959-2	2021	Therefore, in this work, based on introducing 3,4,5-trimethoxy phenyl group as a part of the CAP moiety, in addition to incorporating 4-6 aliphatic carbons linker and using COOH or hydroxamic acid as ZBG, 12 novel EGFR/HDAC hybrid inhibitors 2a-c, 3a-c, 4a-c and 5a-c were designed, constructed, and evaluated for their anticancer activities against 4 cancer cell lines (HepG2, MCF-7, HCT116 and A549).	Hydroxamic Acids	181-196	epidermal growth factor receptor	Homo sapiens	214-218
34834312-6	2021	According to the in vitro testing, hydroxamic acids 15 and 25, which effectively inhibited HDAC6 and exhibited anti-aggregation properties against beta-amyloid peptides, were chosen as the most promising substances to study their neuroprotective activities in vivo.	Hydroxamic Acids	35-51	histone deacetylase 6	Mus musculus	91-96
34648295-2	2021	But here, we discovered a series of hydroxamic acid-based microtubule destabilizing agents (MDAs), which were derived from shortening the length of the linker in HDAC6 inhibitor SKLB-23bb.	Hydroxamic Acids	36-51	histone deacetylase 6	Homo sapiens	162-167
34153811-2	2021	As a pivotal strategy for drug discovery,molecular hybridization was introduced in this study and a series of pyrrolo(2,1-c)(1,4) benzodiazepine-3,11-diones (PBDs) based hydroxamic acids was rationally designed and synthesizedas novel selective HDAC6 inhibitors.	Hydroxamic Acids	170-186	histone deacetylase 6	Homo sapiens	245-250
34567959-1	2021	This present study reports some natural products and one hydroxamic acid synthetic compound which were previously reported as matrix metalloproteinase-9 (MMP-9) inhibitors to be evaluated for their inhibition toward severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 3-chymotrypsin-like protease (3CLpro).	Hydroxamic Acids	57-72	matrix metallopeptidase 9	Homo sapiens	126-152
34468295-11	2022	The hydroxamic acid TH34 (HDAC-8 and 10 IC50 = 1.9 microM and 7.7 microM, respectively) and the hybrid derivatives 46d, 46e and 46g were the most promising both in terms of potency and selectivity.	Hydroxamic Acids	4-19	histone deacetylase 8	Homo sapiens	26-32
34497879-1	2021	Since the approval of three hydroxamic acid-based HDAC inhibitors as anticancer drugs, such functional groups acquired even more notoriety in synthetic medicinal chemistry.	Hydroxamic Acids	28-43	histone deacetylase 9	Homo sapiens	50-54
34369509-4	2021	Typically, HDAC2 inhibitors interact with the Zn2+ ions through the core chelate group, while HDAC8 inhibitors adopt a bent conformation within the HDAC8 pocket that inclines to be in contact with the Zn2+ ions through the terminal hydroxamic acid group.	Hydroxamic Acids	232-247	histone deacetylase 8	Homo sapiens	94-99
34369509-4	2021	Typically, HDAC2 inhibitors interact with the Zn2+ ions through the core chelate group, while HDAC8 inhibitors adopt a bent conformation within the HDAC8 pocket that inclines to be in contact with the Zn2+ ions through the terminal hydroxamic acid group.	Hydroxamic Acids	232-247	histone deacetylase 8	Homo sapiens	148-153
34567959-1	2021	This present study reports some natural products and one hydroxamic acid synthetic compound which were previously reported as matrix metalloproteinase-9 (MMP-9) inhibitors to be evaluated for their inhibition toward severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 3-chymotrypsin-like protease (3CLpro).	Hydroxamic Acids	57-72	matrix metallopeptidase 9	Homo sapiens	154-159
34865583-0	2021	A novel tin based hydroxamic acid complex induces apoptosis through redox imbalance and targets Stat3/JNK1/MMP axis to overcome drug resistance in cancer.	Hydroxamic Acids	18-33	mitogen-activated protein kinase 8	Homo sapiens	102-106
35630812-11	2022	The interaction pattern analysis showed that the alpha-amino amide moiety of 7a coordinated with the zinc ion of HDAC6 in a bidentate chelate manner, which is similar to the chelation pattern of hydroxamic acid.	Hydroxamic Acids	195-210	histone deacetylase 6	Homo sapiens	113-118
35005974-0	2022	N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment.	Hydroxamic Acids	34-50	monoamine oxidase A	Homo sapiens	73-92
35005974-0	2022	N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment.	Hydroxamic Acids	34-50	histone deacetylase 9	Homo sapiens	97-116
35005974-4	2022	We have synthesized and evaluated N-methylpropargylamine-conjugated hydroxamic acids as dual inhibitors of MAO A and HDAC.	Hydroxamic Acids	68-84	monoamine oxidase A	Homo sapiens	107-112
35005974-4	2022	We have synthesized and evaluated N-methylpropargylamine-conjugated hydroxamic acids as dual inhibitors of MAO A and HDAC.	Hydroxamic Acids	68-84	histone deacetylase 9	Homo sapiens	117-121
35204163-0	2022	Hydroxamic Acid as a Potent Metal-Binding Group for Inhibiting Tyrosinase.	Hydroxamic Acids	0-15	tyrosinase	Homo sapiens	63-73
35204163-3	2022	In this study, we report that hydroxamic acid is a potent metal-binding group for interacting with dicopper atoms, thereby inhibiting tyrosinase.	Hydroxamic Acids	30-45	tyrosinase	Homo sapiens	134-144
35305483-0	2022	HDAC1/MAO-B dual inhibitors against Alzheimer"s disease: Design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids.	Hydroxamic Acids	121-136	histone deacetylase 1	Rattus norvegicus	0-5
35305483-0	2022	HDAC1/MAO-B dual inhibitors against Alzheimer"s disease: Design, synthesis and biological evaluation of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids.	Hydroxamic Acids	121-136	monoamine oxidase B	Rattus norvegicus	6-11
35305483-1	2022	A series of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids inhibitors combining the typical pharmacophores of hydroxamic acid/o-aminobenzamide and propargylamine were designed and synthesized as HDAC1/MAO-B dual inhibitors for the treatment of Alzheimer"s disease.	Hydroxamic Acids	29-44	histone deacetylase 1	Rattus norvegicus	206-211
35305483-1	2022	A series of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids inhibitors combining the typical pharmacophores of hydroxamic acid/o-aminobenzamide and propargylamine were designed and synthesized as HDAC1/MAO-B dual inhibitors for the treatment of Alzheimer"s disease.	Hydroxamic Acids	29-44	monoamine oxidase B	Rattus norvegicus	212-217
35305483-1	2022	A series of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids inhibitors combining the typical pharmacophores of hydroxamic acid/o-aminobenzamide and propargylamine were designed and synthesized as HDAC1/MAO-B dual inhibitors for the treatment of Alzheimer"s disease.	Hydroxamic Acids	121-136	histone deacetylase 1	Rattus norvegicus	206-211
35305483-1	2022	A series of N-propargylamine-hydroxamic acid/o-aminobenzamide hybrids inhibitors combining the typical pharmacophores of hydroxamic acid/o-aminobenzamide and propargylamine were designed and synthesized as HDAC1/MAO-B dual inhibitors for the treatment of Alzheimer"s disease.	Hydroxamic Acids	121-136	monoamine oxidase B	Rattus norvegicus	212-217
34865583-0	2021	A novel tin based hydroxamic acid complex induces apoptosis through redox imbalance and targets Stat3/JNK1/MMP axis to overcome drug resistance in cancer.	Hydroxamic Acids	18-33	signal transducer and activator of transcription 3	Homo sapiens	96-101